Skip to main content
. Author manuscript; available in PMC: 2012 Apr 30.
Published in final edited form as: Cancer Res. 2010 Aug 18;70(19):7534–7542. doi: 10.1158/0008-5472.CAN-10-0815

Fig 1.

Fig 1

Analysis of joint odds ratio (OR) of sCD23 and sCD14 in glioblastoma (GBM) patients taking or not taking dexamethasone. The patients were stratified into four groups by ln sCD14 and ln s CD23 values (ln sCD14 <2.23 or >2.23, ln sCD23 <0.46 or >0.46). A. In GBM patients who were not taking dexamethasone at the time of blood draw the OR in the group with high sCD14 and low sCD23 was more than 6.8-fold higher than the group with the low sCD14 and high sCD23 values. B. In GBM patients who were taking dexamethosone the OR in the high sCD14 and low sCD23 was more than 14-fold higher than those with the low sCD14 and high sCD23 values.